|
Cyclacel Pharmaceuticals, Inc.
Ticker Symbol: CYCC CUSIP: 23254L405 Previous CUSIP: 23254L306 Exchange: NGM
May 31, 2016 -- Cyclacel Pharmaceuticals, Inc. (CYCC) will effect a one-for-twelve (1-12) reverse split and the CUSIP number will change to 23254L405._______________August 27, 2012, 1-for-7 reverse stock split.
|
Company's Online Profile
BUSINESS: Cyclacel Pharmaceuticals is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. The Company's corporate headquarters are in Berkeley Heights, New Jersey, where its business development and medical and regulatory functions are also located. The company's primary research facility is located in Dundee, Scotland.
|
Find All Related Securities for CYCC
Link to IPO Prospectus
Previous Ticker Symbol: XCYT Changed: 3/28/2006
Previous Name: Xcyte Therapies, Inc. Changed: 3/28/2006
Micro Cap Stock -
Market Value $ Million
Click for current CYCC price quote from the NASDAQ
|
Company's Online Information Links
|
| Company's Online SEC EDGAR Filings |
| Company's Email Address Links |
| Address and Phone Numbers |
| Address: 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922 |
| Main Phone Number |
908-517-7330 |
| Fax Number |
866-271-3466 |
| Investor Contact (CFO)
Paul McBarron
|
908-517-7330
|
Toll Free Phone Number |
Unknown |
| CEO - Spiro Rombotis |
CFO - Paul McBarron |
Find a problem? Please use our Feedback Page or Email us.
Have you filled out our Guestbook? If not, please do.
|
|
